PCSK9 inhibitors for COVID-19: an opportunity to enhance the antiviral action of interferon in patients with hypercholesterolaemia

被引：31
作者：
Vuorio, A. [1 ,2 ]
Kovanen, P. T. [3 ]
机构：
[1] Mehilainen Airport Hlth Ctr, Vantaa 01530, Finland
[2] Univ Helsinki, Dept Forens Med, Helsinki, Finland
[3] Wihuri Res Inst, Helsinki, Finland
来源：
JOURNAL OF INTERNAL MEDICINE | 2021年 / 289卷 / 05期
关键词：
D O I：
10.1111/joim.13210
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：749 / 751
页数：3
相关论文
共 11 条
[1]   Mutations in PCSK9 cause autosomal dominant hypercholesterolemia [J].
Abifadel, M ;
Varret, M ;
Rabès, JP ;
Allard, D ;
Ouguerram, K ;
Devillers, M ;
Cruaud, C ;
Benjannet, S ;
Wickham, L ;
Erlich, D ;
Derré, A ;
Villéger, L ;
Farnier, M ;
Beucler, I ;
Bruckert, E ;
Chambaz, J ;
Chanu, B ;
Lecerf, JM ;
Luc, G ;
Moulin, P ;
Weissenbach, J ;
Prat, A ;
Krempf, M ;
Junien, C ;
Seidah, NG ;
Boileau, C .
NATURE GENETICS, 2003, 34 (02) :154-156
[2]  
[Anonymous], SCIENCE
[3]   Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1) [J].
Canuel, Maryssa ;
Sun, Xiaowei ;
Asselin, Marie-Claude ;
Paramithiotis, Eustache ;
Prat, Annik ;
Seidah, Nabil G. .
PLOS ONE, 2013, 8 (05)
[4]  
Gan ES, 2020, J CLIN INVEST, V130, P5223, DOI [10.1172/JCI137536, 10.1172/JCI137536.]
[5]   Increased Expression of LDL Receptor-Related Protein 1 during Human Cytomegalovirus Infection Reduces Virion Cholesterol and Infectivity [J].
Gudleski-O'Regan, Nicole ;
Greco, Todd M. ;
Cristea, Ileana M. ;
Shenk, Thomas .
CELL HOST & MICROBE, 2012, 12 (01) :86-96
[6]   Meta-analysis of Effect of Statins in Patients with COVID-19 [J].
Kow, Chia Siang ;
Hasan, Syed Shahzad .
AMERICAN JOURNAL OF CARDIOLOGY, 2020, 134 :153-155
[7]   Proprotein convertase subtilisin/kexin type 9 inhibits interferon β expression through interacting with ATF-2 [J].
Li, Zhubing ;
Liu, Qiang .
FEBS LETTERS, 2018, 592 (13) :2323-2333
[8]   May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects? [J].
Scicali, Roberto ;
Di Pino, Antonino ;
Piro, Salvatore ;
Rabuazzo, Agata M. ;
Purrello, Francesco .
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2020, 30 (07) :1068-1069
[9]   Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities [J].
Vuorio, A. ;
Watts, G. F. ;
Schneider, W. J. ;
Tsimikas, S. ;
Kovanen, P. T. .
JOURNAL OF INTERNAL MEDICINE, 2020, 287 (01) :2-18
[10]   Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia [J].
Vuorio, Alpo ;
Kovanen, Petri T. .
JOURNAL OF CLINICAL LIPIDOLOGY, 2020, 14 (05) :617-618
12